Kai Neben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kai Neben has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Alwin Kraemer
2 shared publicationsAxel Benner
2 shared publications- Hartmut Goldschmidt
Medizinische Klinik und Poliklinik V, Universität Heidelberg
2 shared publications J Hillengass
2 shared publicationsT Moehler
2 shared publicationsA Benner
1 shared publication
Latest Publications
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 6722
Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin’s-lymphoma: First interim results of a prospective randomised phase II study
6722 Background: Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. Methods: To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m2) every 3 months for 2 years. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. Results: So far 44 patients (pts) with CD20+ B-cell Non-Hodgkins-Lymphoma were enrolled in this trial. Histological subtypes included diffuse large cell lymphoma (21 pts), follicular lymphoma (10 pts), mantle cell lymphoma (6 pts), primary mediastinal lymphoma (5 pts), marginal zone lymphoma (1 pt) and unclassified B-cell lymphoma (1 pt). No severe adverse events were observed during rituximab maintenance therapy. To date, all patients in the rituximab maintenance treatment arm are in continuous clinical remission. Importantly, in the observation arm 3 patients have relapsed. Conclusions: We conclude that rituximab maintenance therapy is feasable, safe and well tolerated in patients with CD20+ B-cell Non-Hodgkins-Lymphoma and might protect against tumor relapse. Patient recruitment for this study is ongoing. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 6722
Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin’s-lymphoma: First interim results of a prospective randomised phase II study
6722 Background: Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. Methods: To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m2) every 3 months for 2 years. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. Results: So far 44 patients (pts) with CD20+ B-cell Non-Hodgkins-Lymphoma were enrolled in this trial. Histological subtypes included diffuse large cell lymphoma (21 pts), follicular lymphoma (10 pts), mantle cell lymphoma (6 pts), primary mediastinal lymphoma (5 pts), marginal zone lymphoma (1 pt) and unclassified B-cell lymphoma (1 pt). No severe adverse events were observed during rituximab maintenance therapy. To date, all patients in the rituximab maintenance treatment arm are in continuous clinical remission. Importantly, in the observation arm 3 patients have relapsed. Conclusions: We conclude that rituximab maintenance therapy is feasable, safe and well tolerated in patients with CD20+ B-cell Non-Hodgkins-Lymphoma and might protect against tumor relapse. Patient recruitment for this study is ongoing. No significant financial relationships to disclose.
- 26 August 2004
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 176 (09) , 1285-1295
Dynamische MRT des Knochenmarks zum Monitoring des Multiplen Myeloms unter Thalidomid-Monotherapie oder Kombination mit CED-Chemotherapie
Zielsetzung: Quantifizierung von Veränderungen der Mikrozirkulation im Knochenmark beim Multiplen Myelom (MM) mittels dynamischer MRT (dMRT) unter antiangiogener Therapie mit Thalidomid oder Kombinationstherapie aus Thalidomid und CED (Cyclophosphamid, Etoposid, Dexamethason). Material und Methode: Die Auswertung umfasst 63 Patienten mit rezidiviertem oder refraktärem MM, die vor und im Verlauf der Behandlung eine zeitlich hoch aufgelöste dMRT-Untersuchung (T1w-turboFLASH) der LWS erhielten. Die Kontrastmitteldynamik wurde anhand eines 2-Kompartment-Modells mit den Parametern Amplitude und kep (Austauschratenkonstante) quantifiziert. Die Auswertung wurde vorgenommen unter Berücksichtigung des prätherapeutischen dMRT-Befundes (pathologisch vs. nicht pathologisch) und dem klinischen Ansprechen (Responder vs. Non-Responder). Ergebnisse: Unter Thalidomid-Monotherapie (n = 38) wurden im Verlauf keine signifikanten Veränderungen der dMRT-Parameter beobachtet, auch unter Berücksichtigung des prätherapeutischen dMRT-Befundes (positiv n = 22) und des klinischen Ansprechens (Responder n = 14). Unter Kombinationstherapie (n = 25) zeigten 18 Patienten mit positivem prätherapeutischen dMRT-Befund und klinischem Ansprechen einen signifikanten Rückgang der Austauschratenkonstante (p = 0,01); die Amplitude war in den meisten Fällen rückläufig, letztlich aber ohne statistische Signifikanz (p = 0,09). Schlussfolgerung: Anhand der dMRT sind signifikante Veränderungen der Mikrozirkulation des Knochenmarks nur unter Kombinationstherapie quantifizierbar, nicht unter Thalidomid-Monotherapie. Purpose: To quantify changes of bone marrow microcirculation in multiple myeloma (MM) using contrast enhanced dynamic MRI (dMRI) during thalidomide as antiangiogenic monotherapy or in combination with chemotherapy (cyclophosphamide, etoposide, dexamethasone). Materials and Methods: The study includes 63 patients with refractory or relapsed MM, who underwent dMRI with high temporal resolution (T1w-turboFLASH) of the lumbar spine before and following treatment. The contrast uptake was quantified using a two compartment model with the output parameters amplitude and kep (exchange rate constant). The evaluation considered the initial dMRI finding (pathological or non-pathological) and the clinical therapeutic response (response or no response). Results: During monotherapy with thalidomide (n = 38), no significant changes of the dMRI parameters were found, even when considering the initial dMRI finding (positive n = 22) and the therapeutic response (responder n = 14). The combination with chemotherapy (n = 25) had a significant reduction of kep (p = 0.01) in 18 patients with positive initial dMRI finding and therapeutic response. Reduction of the amplitude was seen in most cases, but in the end without any significance (p = 0.09). Conclusion: dMRI can quantify significant changes of bone marrow microcirculation solely during treatment with thalidomide combined with chemotherapy, not with thalidomide alone.
- 26 August 2004
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 176 (09) , 1285-1295
Dynamische MRT des Knochenmarks zum Monitoring des Multiplen Myeloms unter Thalidomid-Monotherapie oder Kombination mit CED-Chemotherapie
Zielsetzung: Quantifizierung von Veränderungen der Mikrozirkulation im Knochenmark beim Multiplen Myelom (MM) mittels dynamischer MRT (dMRT) unter antiangiogener Therapie mit Thalidomid oder Kombinationstherapie aus Thalidomid und CED (Cyclophosphamid, Etoposid, Dexamethason). Material und Methode: Die Auswertung umfasst 63 Patienten mit rezidiviertem oder refraktärem MM, die vor und im Verlauf der Behandlung eine zeitlich hoch aufgelöste dMRT-Untersuchung (T1w-turboFLASH) der LWS erhielten. Die Kontrastmitteldynamik wurde anhand eines 2-Kompartment-Modells mit den Parametern Amplitude und kep (Austauschratenkonstante) quantifiziert. Die Auswertung wurde vorgenommen unter Berücksichtigung des prätherapeutischen dMRT-Befundes (pathologisch vs. nicht pathologisch) und dem klinischen Ansprechen (Responder vs. Non-Responder). Ergebnisse: Unter Thalidomid-Monotherapie (n = 38) wurden im Verlauf keine signifikanten Veränderungen der dMRT-Parameter beobachtet, auch unter Berücksichtigung des prätherapeutischen dMRT-Befundes (positiv n = 22) und des klinischen Ansprechens (Responder n = 14). Unter Kombinationstherapie (n = 25) zeigten 18 Patienten mit positivem prätherapeutischen dMRT-Befund und klinischem Ansprechen einen signifikanten Rückgang der Austauschratenkonstante (p = 0,01); die Amplitude war in den meisten Fällen rückläufig, letztlich aber ohne statistische Signifikanz (p = 0,09). Schlussfolgerung: Anhand der dMRT sind signifikante Veränderungen der Mikrozirkulation des Knochenmarks nur unter Kombinationstherapie quantifizierbar, nicht unter Thalidomid-Monotherapie. Purpose: To quantify changes of bone marrow microcirculation in multiple myeloma (MM) using contrast enhanced dynamic MRI (dMRI) during thalidomide as antiangiogenic monotherapy or in combination with chemotherapy (cyclophosphamide, etoposide, dexamethasone). Materials and Methods: The study includes 63 patients with refractory or relapsed MM, who underwent dMRI with high temporal resolution (T1w-turboFLASH) of the lumbar spine before and following treatment. The contrast uptake was quantified using a two compartment model with the output parameters amplitude and kep (exchange rate constant). The evaluation considered the initial dMRI finding (pathological or non-pathological) and the clinical therapeutic response (response or no response). Results: During monotherapy with thalidomide (n = 38), no significant changes of the dMRI parameters were found, even when considering the initial dMRI finding (positive n = 22) and the therapeutic response (responder n = 14). The combination with chemotherapy (n = 25) had a significant reduction of kep (p = 0.01) in 18 patients with positive initial dMRI finding and therapeutic response. Reduction of the amplitude was seen in most cases, but in the end without any significance (p = 0.09). Conclusion: dMRI can quantify significant changes of bone marrow microcirculation solely during treatment with thalidomide combined with chemotherapy, not with thalidomide alone.
- 1 November 2002
- Vol. 8 (11) , 3377-82
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial. The aim of this study was to analyze whether the effect of Thal in MM is dose dependent and whether the outcome might be improved when the Thal dosage is adjusted to parameters reflecting body size. From December 1998 to March 2001, 83 patients with relapsed MM were enrolled in a clinical Phase II trial and treated with a maximum Thal dosage of 400 mg daily. We performed a retrospective analysis and studied the effect of the cumulative 3-month Thal dosage on progression-free survival and overall survival (OS) together with age and the pretreatment levels of beta2-microglobulin, C-reactive protein, albumin, and hemoglobin in a Cox regression model. After a median follow-up time of 17 months (range, 1-30 months), the estimated 12-month progression-free survival and OS were 45% (SE = 6%) and 86% (SE = 4%) for the whole patient group. After backward selection, hemoglobin (P = 0.002) and the cumulative 3-month Thal dosage (P = 0.002) were the remaining factors for OS. The effect on OS could not be improved when the cumulative 3-month Thal dosage was adjusted to parameters reflecting body size such as height, weight, body surface area, or body mass index in comparison with Thal alone. Our retrospective analysis demonstrates that the cumulative 3-month Thal dosage is one of the major prognostic factors for OS, supporting the hypothesis of a dose-dependent effect of Thal in relapsed MM.
- 1 November 2002
- Vol. 8 (11) , 3377-82
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial. The aim of this study was to analyze whether the effect of Thal in MM is dose dependent and whether the outcome might be improved when the Thal dosage is adjusted to parameters reflecting body size. From December 1998 to March 2001, 83 patients with relapsed MM were enrolled in a clinical Phase II trial and treated with a maximum Thal dosage of 400 mg daily. We performed a retrospective analysis and studied the effect of the cumulative 3-month Thal dosage on progression-free survival and overall survival (OS) together with age and the pretreatment levels of beta2-microglobulin, C-reactive protein, albumin, and hemoglobin in a Cox regression model. After a median follow-up time of 17 months (range, 1-30 months), the estimated 12-month progression-free survival and OS were 45% (SE = 6%) and 86% (SE = 4%) for the whole patient group. After backward selection, hemoglobin (P = 0.002) and the cumulative 3-month Thal dosage (P = 0.002) were the remaining factors for OS. The effect on OS could not be improved when the cumulative 3-month Thal dosage was adjusted to parameters reflecting body size such as height, weight, body surface area, or body mass index in comparison with Thal alone. Our retrospective analysis demonstrates that the cumulative 3-month Thal dosage is one of the major prognostic factors for OS, supporting the hypothesis of a dose-dependent effect of Thal in relapsed MM.
- 20 December 2001
- Published by Wiley in British Journal of Haematology
- Vol. 115 (3) , 605-608
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
- 20 December 2001
- Published by Wiley in British Journal of Haematology
- Vol. 115 (3) , 605-608
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
- 1 November 2001
- Published by Springer Nature in Annals of Hematology
- Vol. 80 (11) , 682-684
A man with hereditary exostoses and high-grade non-Hodgkin's lymphoma of the bone
Multiple cartilaginous exostoses (MCE) is an autosomal dominant disorder that can lead to malignant transformation from exostoses to a secondary chondrosarcoma. We present a case report of a 52-year-old man with MCE who had a palpable mass at the left shoulder. At the site of the left proximal humerus, a cartilaginous exostosis was localized, suggesting that the tumor developed by a malignant transformation of an exostosis into a secondary chondrosarcoma. Interestingly, a biopsy showed a diffuse large B-cell lymphoma with Burkitt-like features. To our knowledge, the association of high-grade lymphoma and hereditary exostoses has not been described previously. This case demonstrates that a malignant tumor at the location of a cartilaginous exostosis is not necessarily a chondrosarcoma and that a biopsy is an essential part of the diagnostic work-up.
- 1 November 2001
- Published by Springer Nature in Annals of Hematology
- Vol. 80 (11) , 682-684
A man with hereditary exostoses and high-grade non-Hodgkin's lymphoma of the bone
Multiple cartilaginous exostoses (MCE) is an autosomal dominant disorder that can lead to malignant transformation from exostoses to a secondary chondrosarcoma. We present a case report of a 52-year-old man with MCE who had a palpable mass at the left shoulder. At the site of the left proximal humerus, a cartilaginous exostosis was localized, suggesting that the tumor developed by a malignant transformation of an exostosis into a secondary chondrosarcoma. Interestingly, a biopsy showed a diffuse large B-cell lymphoma with Burkitt-like features. To our knowledge, the association of high-grade lymphoma and hereditary exostoses has not been described previously. This case demonstrates that a malignant tumor at the location of a cartilaginous exostosis is not necessarily a chondrosarcoma and that a biopsy is an essential part of the diagnostic work-up.
- 1 September 2001
- Vol. 7 (9) , 2675-81
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54). We examined the concentration of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), two potent heparin-binding mediators of angiogenesis in peripheral blood (PB; PB-VEGF and PB-bFGF) and bone marrow (BM; BM-VEGF and BM-bFGF), in combination with well-characterized predictors for response and survival to chemotherapy. After a median follow-up time of 15 months (range, 0.3-20), 29 patients (pts.) showed at least a minimal response to Thal therapy, whereas 25 pts. were nonresponsive. As shown by univariate analysis, responsive pts. had statistically significant higher concentrations of PB-bFGF (P = 0.009) and beta2-microglobulin (P = 0.03) before therapy, as well as lower hemoglobin (P = 0.008) and albumin (P = 0.02) levels, whereas no statistically significant difference was found for PB-VEGF (P = 0.93). When a multiple logistic regression analysis was performed, PB-bFGF was the only statistically significant predictor for response to therapy (P = 0.01). None of these variables was associated with a prolonged progression-free survival. In conclusion, our findings indicate that high pretreatment plasma bFGF levels in pts. with progressive multiple myeloma are associated with unfavorable parameters of response and survival but nevertheless predict for response to Thal therapy.
- 1 September 2001
- Vol. 7 (9) , 2675-81
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54). We examined the concentration of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), two potent heparin-binding mediators of angiogenesis in peripheral blood (PB; PB-VEGF and PB-bFGF) and bone marrow (BM; BM-VEGF and BM-bFGF), in combination with well-characterized predictors for response and survival to chemotherapy. After a median follow-up time of 15 months (range, 0.3-20), 29 patients (pts.) showed at least a minimal response to Thal therapy, whereas 25 pts. were nonresponsive. As shown by univariate analysis, responsive pts. had statistically significant higher concentrations of PB-bFGF (P = 0.009) and beta2-microglobulin (P = 0.03) before therapy, as well as lower hemoglobin (P = 0.008) and albumin (P = 0.02) levels, whereas no statistically significant difference was found for PB-VEGF (P = 0.93). When a multiple logistic regression analysis was performed, PB-bFGF was the only statistically significant predictor for response to therapy (P = 0.01). None of these variables was associated with a prolonged progression-free survival. In conclusion, our findings indicate that high pretreatment plasma bFGF levels in pts. with progressive multiple myeloma are associated with unfavorable parameters of response and survival but nevertheless predict for response to Thal therapy.